ICP-MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22CuN6O4 as the complex | Free peptide is C14H24N6O4 |
| Molecular weight | About 402 g/mol | Free peptide is about 340 g/mol |
| Appearance | Blue solid or blue solution | Color from copper d-d transitions |
| Solubility class | Water-soluble; poor in nonpolar solvents | Ionic character favors aqueous media |
| Common synonyms | Copper tripeptide-1; glycyl-L-histidyl-L-lysine copper | INCI listing uses copper tripeptide-1 |
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
Stability of the complex in solution depends on pH, temperature, and the presence of competing ligands. It is generally described as more resistant to breakdown than the metal-free chain, since coordination reduces susceptibility to enzymatic attack. Oxidation and hydrolysis can nevertheless proceed over time in aqueous media. Storage guidance in laboratory settings commonly involves refrigeration, protection from light, and avoidance of strongly alkaline conditions. Published data on long-term behaviour vary considerably and depend on the specific matrix.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
== Good country == The Good Country Index seeks to measure every country's "contribution to the common good of humanity and the planet". Of 153 nations ranked in 2018, Thailand ranked 60 (1=best; 153=worst). Other ASEAN nations were ranked: Singapore, 23; Malaysia, 45; Philippines, 69; Brunei, 70; Indonesia, 87; Vietnam, 116; Cambodia, 130; Laos, 134. Myanmar was not included due to lack of data.
==== Basic metabolic studies ==== Biochemical studies are performed to screen for imbalances of metabolites in the bodily fluid, usually the blood (plasma/serum) or urine, but also in cerebrospinal fluid (CSF). Specific tests of enzyme function (either in leukocytes, skin fibroblasts, liver, or muscle) are also employed under certain circumstances. In the US, the newborn screen incorporates biochemical tests to screen for treatable conditions such as galactosemia and phenylketonuria (PKU). Patients suspected to have a metabolic condition might undergo the following tests:
One may visualize an oligonucleotide microarray as a miniature multi-well plate where physical dividers between the wells (plastic walls) are intentionally removed. With respect to the chemistry, synthesis of oligonucleotide microarrays is different from the conventional oligonucleotide synthesis in two respects:
Milnacipran has low molecular weight and low lipophilicity. Because of these properties, milnacipran exhibits almost ideal pharmacokinetics in humans such as high bioavailability, low inter-subject variability, limited liver enzyme interaction, moderate tissue distribution and a reasonably long elimination half-life. Milnacipran's lack of drug-drug interactions via cytochrome P450 enzymes is thought to be an attractive feature because many of the central nervous system drugs are highly lipophilic and are mainly eliminated by liver enzymes.
=== Notable users === József Knoll, one of the developers of selegiline, began taking a low 1 mg daily dose of selegiline on January 1, 1989, at the age of 64. He reported in 2012 that this had continued for 22 years uninterrupted. Knoll stated that he had become so fascinated with the possible longevity-promoting effects of selegiline that he had decided to start taking it as a self-experiment. Knoll later died in 2018 at the age of 93. David Pearce, a British transhumanist philosopher, wrote his self-published book-length internet manifesto The Hedonistic Imperative six weeks after starting to take selegiline. Hamilton Morris, a psychoactive drug journalist and researcher, appears to have used selegiline. Sam Bankman-Fried, the founder and former CEO of the FTX cryptocurrency exchange, is known to have used selegiline for depression in the form of the Emsam patch for at least 5 to 10 years. He is also known to have simultaneously taken Adderall for treatment of attention deficit hyperactivity disorder (ADHD) and to have possessed non-pharmaceutical adrafinil, a prodrug of modafinil.
Sources: en.wikipedia.org
In 1933, Fermi published his landmark theory for beta decay, where he applied the principles of quantum mechanics to matter particles, supposing that they can be created and annihilated, just as the light quanta in atomic transitions. Thus, according to Fermi, neutrinos are created in the beta-decay process, rather than contained in the nucleus; the same happens to electrons. The neutrino interaction with matter was so weak that detecting it proved a severe experimental challenge. Further indirect evidence of the existence of the neutrino was obtained by observing the recoil of nuclei that emitted such a particle after absorbing an electron. Neutrinos were finally detected directly in 1956 by the American physicists Clyde Cowan and Frederick Reines in the Cowan–Reines neutrino experiment. The properties of neutrinos were (with a few minor modifications) as predicted by Pauli and Fermi.
== History == Ken and Linda Rosenthal founded the St. Louis Bread Company in 1987 after Ken visited sourdough bakery-café La Boulanger in San Francisco at the insistence of his brother. After being fascinated with the process of sourdough making, he was trained to make sourdough under instruction of the owner, Roger Brunello for a year. The first location was opened in Kirkwood, Missouri. The Rosenthals invested $150,000 and received a $150,000 Small Business Administration loan. Au Bon Pain Co., a public company, purchased the St. Louis Bread Company in 1993 for $23 million. In 1997, Au Bon Pain changed the company name to Panera, from a word that has roots in the Latin word for "breadbasket" (Classical pānārium, Vulgar pānāria) and is identical to the word for "breadbasket" in Spanish and Catalan. The original name was retained for locations in Missouri. At the same time, the St. Louis Bread Company renovated its 20 bakery-cafes in the St. Louis area. In May 1999, Au Bon Pain Co. sold the Au Bon Pain chain to the firm Bruckmann, Rosser, Sherrill & Co. for $78 million to focus on the Panera Bread chain. In 2000, Panera Bread moved its headquarters to Richmond Heights, Missouri. In 2007, Panera Bread purchased a 51% stake in Paradise Bakery & Café, a Phoenix metropolitan area-based concept with over 70 locations in 10 states, predominantly in the West and Southwest, for $21.1 million. The company purchased the balance of Paradise in June 2009.
=== Bjerknes feedback === The close relationship between ocean temperatures and the strength of the trade winds was first identified by Jacob Bjerknes in 1969. Bjerknes also hypothesized that ENSO was a positive feedback system where the associated changes in one component of the climate system (the ocean or atmosphere) tend to reinforce changes in the other. This process is known as Bjerknes feedback. For example, during the growth of El Niño, the reduced contrast in ocean temperatures across the Pacific results in weaker trade winds, further reinforcing the El Niño state. Although these associated changes in the ocean and atmosphere often occur together, the state of the atmosphere may resemble a different ENSO phase than the state of the ocean or vice versa. Because their states are closely linked, the variations of ENSO may arise from changes in both the ocean and atmosphere and not necessarily from an initial change of exclusively one or the other. Conceptual models explaining how ENSO operates generally accept the Bjerknes feedback hypothesis. However, ENSO would perpetually remain in one phase if Bjerknes feedback were the only process occurring. Several theories have been proposed to explain how ENSO can change from one state to the next despite the positive feedback. These explanations broadly fall under two categories. In one view, the Bjerknes feedback naturally triggers negative feedbacks that end and reverse the abnormal state of the tropical Pacific.
In some neurodegenerative diseases, alpha-synuclein produces insoluble inclusion bodies. These diseases, known as synucleinopathies, are connected with either higher levels of normal alpha-synuclein or its mutant variants. The normal physiological role of Snca, however, has not yet been thoroughly explained. In fact, physiological Snca has been demonstrated to have a neuroprotective impact by inhibiting apoptosis induced by several types of apoptotic stimuli, or by regulating the expression of proteins involved in apoptotic pathways. Recently it has been demonstrated that up-regulation of alpha-synuclein in the dentate gyrus (a neurogenic niche where new neurons are generated throughout life) activates stem cells, in a model of premature neural aging. This model shows reduced expression of alpha-synuclein and reduced proliferation of stem cells, as is physiologically observed during aging. Exogenous alpha-synuclein in the dentate gyrus is able to rescue this defect. Moreover, alpha-synuclein also boosts the proliferation of dentate gyrus progenitor neural cells in wild-type young mice. Thus, alpha-synuclein represents an effector for neural stem and progenitor cell activation. Similarly, alpha-synuclein has been found to be required to maintain stem cells of the subventricular zone another neurogenic niche, in a cycling state.
==== Manufacturing process ==== The process for making the americium used in the buttons on ionization-type smoke detectors begins with americium dioxide. The 241AmO2 is thoroughly mixed with gold, shaped into a briquette, and fused by pressure and heat at over 1,470 °F (800 °C). A backing of silver and a front covering of gold (or an alloy of gold or palladium) are applied to the briquette and sealed by hot forging. The briquette is then processed through several stages of cold rolling to achieve the desired thickness and levels of radiation emission. The final thickness is about 0.008 inches (0.20 mm), with the gold cover representing about one percent of the thickness. The resulting foil strip, which is about 0.8 inches (20 mm) wide, is cut into sections 39 inches (1 m) long. The sources are punched out of the foil strip. Each disc, about 0.2 inches (5.1 mm) in diameter, is mounted in a metal holder, usually made of aluminium. The holder is the housing, which is the majority of what is seen on the button. The thin rim on the holder is rolled over to completely seal the cut edge around the disc.
Sources: en.wikipedia.org
=== Mechanism of action === Albiglutide acts as an agonist at the GLP-1 receptor, which makes it a type of incretin mimetic. This causes an increase of insulin secretion, predominantly in the presence of high blood glucose, and also slows down gastric emptying. Unlike other GLP-1 agonists, due to its structure it has difficulty in crossing the blood-brain barrier. This means that it does not affect the central nervous system as much as other GLP-1 agonists and may be responsible for the limited weight loss seen in the drug.
In genomics, annotation refers to the process of marking the stop and start regions of genes and other biological features in a sequenced DNA sequence. Many genomes are too large to be annotated by hand. As the rate of sequencing exceeds the rate of genome annotation, genome annotation has become the new bottleneck in bioinformatics. Genome annotation can be classified into three levels: the nucleotide, protein, and process levels. Gene finding is a chief aspect of nucleotide-level annotation. For complex genomes, a combination of ab initio gene prediction and sequence comparison with expressed sequence databases and other organisms can be successful. Nucleotide-level annotation also allows the integration of genome sequence with other genetic and physical maps of the genome. The principal aim of protein-level annotation is to assign function to the protein products of the genome. Databases of protein sequences and functional domains and motifs are used for this type of annotation. About half of the predicted proteins in a new genome sequence tend to have no obvious function. Understanding the function of genes and their products in the context of cellular and organismal physiology is the goal of process-level annotation. An obstacle of process-level annotation has been the inconsistency of terms used by different model systems. The Gene Ontology Consortium is helping to solve this problem.
The amount of q in a region increases when additional q flows inward through the surface of the region, and decreases when it flows outward; The amount of q in a region increases when new q is created inside the region, and decreases when q is destroyed; Apart from these two processes, there is no other way for the amount of q in a region to change. Mathematically, the integral form of the continuity equation expressing the rate of increase of q within a volume V is:
== Names == Calcitriol refers specifically to 1,25-dihydroxycholecalciferol. Because cholecalciferol already has one hydroxyl group, only two (1,25) are further specified in this nomenclature, but in fact there are three (1,3,25-triol), as indicated by the name calcitriol. The 1-hydroxy group is in the alpha position, and this may be specified in the name, for instance in the abbreviation 1α,25-(OH)2D3. It is also known as cholecalcitriol to emphasize its derivation from vitamin D3. Calcitriol is, strictly, the 1-hydroxylation product of calcifediol (25-OH vitamin D3), derived from cholecalciferol (vitamin D3), rather than the product of hydroxylations of ergocalciferol (vitamin D2). 1α,25-Dihydroxyergocalciferol (ercalcitriol) should be used for the vitamin D2 product. However, the terminology of 1,25-dihydroxyvitamin D, or 1,25(OH)2D, is often used to refer to both types of active forms of vitamin D. Indeed, both bind to the vitamin D receptor and produce biological effects. In clinical use, the differences are unlikely to have major importance. Calcitriol is marketed as a pharmaceutical for medical use under various brand names including Rocaltrol (Roche), Calcijex (Abbott), Decostriol (Mibe, Jesalis), Vectical (Galderma), and Rolsical (Sun Pharma).
== Computer-aided drug design == The most fundamental goal in drug design is to predict whether a given molecule will bind to a target and if so how strongly. Molecular mechanics or molecular dynamics is most often used to estimate the strength of the intermolecular interaction between the small molecule and its biological target. These methods are also used to predict the conformation of the small molecule and to model conformational changes in the target that may occur when the small molecule binds to it. Semi-empirical, ab initio quantum chemistry methods, or density functional theory are often used to provide optimized parameters for the molecular mechanics calculations and also provide an estimate of the electronic properties (electrostatic potential, polarizability, etc.) of the drug candidate that will influence binding affinity. Molecular mechanics methods may also be used to provide semi-quantitative prediction of the binding affinity. Also, knowledge-based scoring function may be used to provide binding affinity estimates. These methods use linear regression, machine learning, neural nets or other statistical techniques to derive predictive binding affinity equations by fitting experimental affinities to computationally derived interaction energies between the small molecule and the target. Ideally, the computational method will be able to predict affinity before a compound is synthesized and hence in theory only one compound needs to be synthesized, saving enormous time and cost.
Sources: en.wikipedia.org
It is the copper(II) complex of the tripeptide glycyl-L-histidyl-lysine, a sequence of three amino acids. The copper ion is held by the histidine imidazole, the terminal amino group, and an amide nitrogen. The bound form is distinct from the free peptide in charge, color, and stability.
Copper(II) complexes absorb light in the red part of the visible spectrum, so transmitted light appears blue. The absorption arises from electronic transitions within the copper d-orbitals, which are split by the surrounding ligands. The intensity and exact wavelength shift somewhat with pH, solvent, and ligand arrangement.
The free peptide and the copper-bound complex are studied as separate species and do not always behave the same way in assays. Some reported responses are attributed to copper delivery, while others are attributed to the peptide sequence itself. Which fraction drives a given observation is often unresolved in the published work.
Lyophilized material is normally held at about minus twenty degrees Celsius in a sealed, desiccated vial. Dissolved samples are less durable and are prepared fresh. Repeated freeze-thaw cycles are avoided.